Friday, October 29, 2021 12:00:59 PM
It usually goes like this: a biotech company develops a drug or biological product; have a review meeting with RAs for submitting NDA or BLA; NDA/BLA submission for application; application reviewed; labeling; manufacturing facility inspection; drug/biological product approval or issuance of a response letter.
So why the company has decided to move this last step backward, or the company has actually delayed all other steps to close to or coincide with this last step?
Why it took MHRA a whole few months to finally set its feet on the facility for inspection. A merely caseload as excuse seems convenient not concrete.
Discount Linda's evil motives to fund Advent to a commercial scale at the cost of nwbio shareholders while maintaining this prolonged quiet period, because the odds of DCVax-L gets approved is very high and she can also build Advent after D is approved.
So is this recently happened MHRA inspection of Sawston facility is equivalent to the LAST STEP of the DCVax-L approval process, besides the obvious Advent license application?
So is it reasonable to think when MHRA issues a license to Advent, it in effect approves the commercial use of DCVax-L in UK at least?
Then within the next couple of months, we will see license issuance, shortly followed by approval of DCVax-L.
When approved, NWBio will easily be worthy of $10-20 billions in short to medium term which is equivalent to a share price in the range of about $10-20 per share.
Yes selling at merely $1 and $1.10 per share instead of buying or holding, the Linda friendlies Island boys and vulture funds have no brains.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM